Bio-Rad Laboratories (BIO) Net Equity Issued and Repurchased (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Net Equity Issued and Repurchased data on file, last reported at $3.4 million in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased fell 20.93% year-over-year to $3.4 million in Q1 2026; TTM through Mar 2026 was $15.3 million, a 21.94% decrease from a year earlier, with the FY2019 full-year figure at $13.1 million, down 7.22% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $3.4 million, roughly flat from $3.4 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for BIO reached as high as $7.6 million in Q3 2022 and fell as low as $3.4 million in Q3 2025.
• Historically, Net Equity Issued and Repurchased has averaged $4.7 million across 5 years, with a median of $4.4 million in 2023.
• Across the five-year window, Net Equity Issued and Repurchased surged 148.84% in 2022 and slumped 33.33% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $7.6 million in 2022, then tumbled by 32.3% to $5.1 million in 2023, then retreated by 0.22% to $5.1 million in 2024, then plunged by 33.33% to $3.4 million in 2025, then changed by 0.0% to $3.4 million in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $3.4 million in Q1 2026, $3.4 million in Q3 2025, and $4.2 million in Q2 2025.